191 related articles for article (PubMed ID: 35790779)
1. Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment.
Wallace-Povirk A; Rubinsak L; Malysa A; Dzinic SH; Ravindra M; Schneider M; Glassbrook J; O'Connor C; Hou Z; Kim S; Back J; Polin L; Morris RT; Gangjee A; Gibson H; Matherly LH
Sci Rep; 2022 Jul; 12(1):11346. PubMed ID: 35790779
[TBL] [Abstract][Full Text] [Related]
2. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
[TBL] [Abstract][Full Text] [Related]
3. Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.
Wilson MR; Hou Z; Yang S; Polin L; Kushner J; White K; Huang J; Ratnam M; Gangjee A; Matherly LH
Mol Pharmacol; 2016 Apr; 89(4):425-34. PubMed ID: 26837243
[TBL] [Abstract][Full Text] [Related]
4. Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer.
Wallace-Povirk A; Hou Z; Nayeen MJ; Gangjee A; Matherly LH
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008360
[TBL] [Abstract][Full Text] [Related]
5. Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
Ravindra M; Wallace-Povirk A; Karim MA; Wilson MR; O'Connor C; White K; Kushner J; Polin L; George C; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2018 Mar; 61(5):2027-2040. PubMed ID: 29425443
[TBL] [Abstract][Full Text] [Related]
6. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
[TBL] [Abstract][Full Text] [Related]
7. Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.
Deis SM; Doshi A; Hou Z; Matherly LH; Gangjee A; Dann CE
Biochemistry; 2016 Aug; 55(32):4574-82. PubMed ID: 27439469
[TBL] [Abstract][Full Text] [Related]
8. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.
Desmoulin SK; Wang Y; Wu J; Stout M; Hou Z; Fulterer A; Chang MH; Romero MF; Cherian C; Gangjee A; Matherly LH
Mol Pharmacol; 2010 Oct; 78(4):577-87. PubMed ID: 20601456
[TBL] [Abstract][Full Text] [Related]
9. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.
Desmoulin SK; Wang L; Polin L; White K; Kushner J; Stout M; Hou Z; Cherian C; Gangjee A; Matherly LH
Mol Pharmacol; 2012 Oct; 82(4):591-600. PubMed ID: 22740639
[TBL] [Abstract][Full Text] [Related]
10. Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
Golani LK; Wallace-Povirk A; Deis SM; Wong J; Ke J; Gu X; Raghavan S; Wilson MR; Li X; Polin L; de Waal PW; White K; Kushner J; O'Connor C; Hou Z; Xu HE; Melcher K; Dann CE; Matherly LH; Gangjee A
J Med Chem; 2016 Sep; 59(17):7856-76. PubMed ID: 27458733
[TBL] [Abstract][Full Text] [Related]
11. 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
Wang L; Wallace A; Raghavan S; Deis SM; Wilson MR; Yang S; Polin L; White K; Kushner J; Orr S; George C; O'Connor C; Hou Z; Mitchell-Ryan S; Dann CE; Matherly LH; Gangjee A
J Med Chem; 2015 Sep; 58(17):6938-59. PubMed ID: 26317331
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
Golani LK; Islam F; O'Connor C; Dekhne AS; Hou Z; Matherly LH; Gangjee A
Bioorg Med Chem; 2020 Jun; 28(12):115544. PubMed ID: 32503687
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.
Wang L; Cherian C; Desmoulin SK; Polin L; Deng Y; Wu J; Hou Z; White K; Kushner J; Matherly LH; Gangjee A
J Med Chem; 2010 Feb; 53(3):1306-18. PubMed ID: 20085328
[TBL] [Abstract][Full Text] [Related]
14. Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.
O'Connor C; Wallace-Povirk A; Ning C; Frühauf J; Tong N; Gangjee A; Matherly LH; Hou Z
Sci Rep; 2021 Mar; 11(1):6389. PubMed ID: 33737637
[TBL] [Abstract][Full Text] [Related]
15. Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
Ravindra M; Wilson MR; Tong N; O'Connor C; Karim M; Polin L; Wallace-Povirk A; White K; Kushner J; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2018 May; 61(9):4228-4248. PubMed ID: 29701475
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.
Cherian C; Kugel Desmoulin S; Wang L; Polin L; White K; Kushner J; Stout M; Hou Z; Gangjee A; Matherly LH
Cancer Chemother Pharmacol; 2013 Apr; 71(4):999-1011. PubMed ID: 23412628
[TBL] [Abstract][Full Text] [Related]
17. Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
Xiang W; Dekhne A; Doshi A; O'Connor C; Hou Z; Matherly LH; Gangjee A
Bioorg Med Chem; 2019 Dec; 27(23):115125. PubMed ID: 31679978
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.
Deng Y; Zhou X; Kugel Desmoulin S; Wu J; Cherian C; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2009 May; 52(9):2940-51. PubMed ID: 19371039
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter.
Kugel Desmoulin S; Wang L; Hales E; Polin L; White K; Kushner J; Stout M; Hou Z; Cherian C; Gangjee A; Matherly LH
Mol Pharmacol; 2011 Dec; 80(6):1096-107. PubMed ID: 21940787
[TBL] [Abstract][Full Text] [Related]
20. Biology and therapeutic applications of the proton-coupled folate transporter.
Matherly LH; Schneider M; Gangjee A; Hou Z
Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):695-706. PubMed ID: 36239195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
